Anixa Biosciences Deferred Revenue 2011-2026 | ANIX

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Anixa Biosciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	-	-	-	-	-	-	1.19 M	1.19 M	1.64 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.64 M	1.19 M	1.34 M

Quarterly Deferred Revenue Anixa Biosciences

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.19 M	-	-	1.19 M	1.19 M	1.19 M	1.19 M	1.19 M	1.44 M	1.19 M	1.19 M	1.19 M	-	1.64 M	1.64 M	1.64 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.64 M	1.19 M	1.31 M

Deferred Revenue of other stocks in the Diagnostics research industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	1.34 M	-	-6.23 %	$ 30.6 M	Germany
Agilent Technologies A	441 M	$ 116.92	2.67 %	$ 35.5 B	USA
Aspira Women's Health AWH	489 K	-	-6.19 %	$ 10.5 M	USA
BioNano Genomics BNGO	967 K	$ 1.18	0.85 %	$ 6.43 M	USA
Chembio Diagnostics CEMI	1.61 M	-	0.22 %	$ 16.8 M	USA
Enzo Biochem ENZ	2.68 M	-	-8.98 %	$ 14.8 K	USA
DermTech DMTK	196 K	-	-11.32 %	$ 2.94 M	USA
CareDx, Inc CDNA	4.65 M	$ 17.92	1.41 %	$ 955 M	USA
Exact Sciences Corporation EXAS	4.14 M	-	-	$ 19.8 B	USA
Oxford Immunotec Global PLC OXFD	19 K	-	-	$ 562 M	Britain
Akumin AKU	7.53 M	-	-17.87 %	$ 25.9 M	Canada
Burning Rock Biotech Limited BNR	143 M	$ 16.24	0.93 %	$ 175 M	China
Co-Diagnostics CODX	14.8 K	$ 4.4	101.83 %	$ 5.85 M	USA
Heska Corporation HSKA	5.08 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	185 K	-	-20.0 %	$ 1.06 M	USA
Interpace Biosciences IDXG	54 K	$ 1.98	-0.63 %	$ 8.76 M	USA
Illumina ILMN	260 M	$ 128.0	1.23 %	$ 20.4 B	USA
Accelerate Diagnostics AXDX	547 K	-	-61.36 %	$ 2.46 M	USA
Castle Biosciences CSTL	6.62 M	$ 25.19	1.45 %	$ 700 M	USA
Global Cord Blood Corporation CO	458 M	-	-	$ 399 M	China
Fluidigm Corporation FLDM	13.5 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	77.3 K	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	8.42 M	-	0.12 %	$ 80.1 M	China
Laboratory Corporation of America Holdings LH	439 M	$ 274.72	2.06 %	$ 22.9 B	USA
Charles River Laboratories International CRL	210 M	$ 175.07	3.26 %	$ 8.68 B	USA
PRA Health Sciences, Inc. PRAH	733 M	-	-	$ 10.7 B	USA
Medpace Holdings MEDP	854 M	$ 520.65	2.39 %	$ 15 B	USA
Danaher Corporation DHR	1.35 B	$ 196.19	2.71 %	$ 140 B	USA
Myriad Genetics MYGN	32.7 M	$ 4.77	0.63 %	$ 442 M	USA
Neogen Corporation NEOG	5.56 M	$ 10.34	3.61 %	$ 2.24 B	USA
National Research Corporation NRC	16.2 M	$ 17.26	1.29 %	$ 386 M	USA
Natera NTRA	10.8 M	$ 210.83	0.75 %	$ 20.7 B	USA
Invitae Corporation NVTA	4.81 M	-	-	$ 21.2 M	USA
Organovo Holdings ONVO	525 K	-	-2.3 %	$ 19.4 M	USA
OpGen OPGN	25.9 K	-	-16.95 %	$ 1.54 M	USA
Fulgent Genetics FLGT	2.23 M	$ 15.83	-0.5 %	$ 479 M	USA
Pacific Biosciences of California PACB	15.9 M	$ 1.47	2.08 %	$ 441 M	USA
Guardant Health GH	50.8 M	$ 92.84	-0.49 %	$ 11.6 B	USA
PerkinElmer PKI	160 M	-	-0.91 %	$ 14.7 B	USA
QIAGEN N.V. QGEN	57.1 M	-	-	$ 10.6 B	Niderland
Psychemedics Corporation PMD	78 K	-	-1.84 %	$ 15.3 M	USA
Personalis PSNL	3.1 M	$ 6.33	2.59 %	$ 375 M	USA
ICON Public Limited Company ICLR	1.61 B	$ 106.54	-0.58 %	$ 8.79 B	Irlanda